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Abstract
Preeclampsia (PE) is the leading cause of preterm birth by medical indication when asso-
ciated with premature detachment of placenta normoinserta, and Intrauterine growth 
restriction (IUGR) is associated with high perinatal morbidity and mortality and long-
term sequelae. The main problem of PE is threefold: the diagnostic difficulty, the com-
plicated interrelationship of the pathophysiological processes, and the vulnerability of 
the maternal-fetal binomial to the therapeutic interventions. The approach for manage-
ment with PE is preventing its late occurrence in pregnancy. The key to preventing PE is 
knowledge of the factors that trigger the pathophysiological processes that culminate in 
the presentation of PE. Understanding the developmental characteristics of the placenta 
in pregnancy at high risk for PE is essential for understanding the pathophysiology and 
developing strategies for prevention. When deciding that the population of study is a 
group of pregnant women, the first ethical criteria that need to be reviewed are those 
aimed at the protection of the fetus. There are no specific guidelines on how to assess 
fetal well-being during pregnancy routinely in the clinic, and this deficiency is shifted to 
clinical research with pregnant women.
Keywords: preeclampsia, eclampsia, pregnancy induced-hypertension, complications in 
pregnancy women
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1. Introduction
Preeclampsia (PE) is the leading cause of preterm birth by medical indication when associ-
ated with premature detachment of placenta normoinserta, and IUGR is associated with high 
perinatal morbidity and mortality and long-term sequelae. It has been described that stan-
dardization in the management of health services and the use of clinical practice guidelines is 
associated with a reduction in adverse outcomes, and a fundamental part of the management 
of severe PE includes a complete evaluation of the mother and the fetus. Despite the advances 
in medicine, the frequency of this syndrome has not changed, and globally its incidence ranges 
between 2 and 10% of pregnancies. The World Health Organization (WHO) estimates that the 
incidence of PE is seven times higher in developing than in developed countries (2.8–0.4%). 
In Mexico, it is estimated that PE is a major cause of maternal and perinatal morbidity and 
mortality. In Jalisco alone, maternal deaths increased to 57.14% from 2011 to 2014, placing this 
state in fourth place at the national level in terms of maternal deaths, during 2015 [1]. Because 
it is a heterogeneous associated idiopathic syndrome to endothelial damage, so far there is no 
effective treatment that reduces the morbidity and mortality of this pathological entity, so it is 
necessary to reinforce prevention. In this area, only the use of calcium supplements and ace-
tylsalicylic acid (ASA) appears to be a recommendation, albeit with controversial results [1, 2].
The main problem of PE is threefold, the diagnostic difficulty, the complicated interrelation-
ship of the pathophysiological processes, and the vulnerability of the maternal-fetal binomial 
to the therapeutic interventions.
2. Pregnant women, scientifically complexed population
There are various concepts about the characteristics of vulnerable populations; however, it is 
generally accepted that a vulnerable group is one whose ability to protect their own interest or 
grant their consent is physically, psychologically, or socially compromised. Since the develop-
ment of ethical principles in research, children, psychiatric patients, prisoners, and pregnant 
women have been included in this group; however, in recent years it has been intended to 
remove pregnant women from this group. The National Institutes of Health (NIH) through the 
Office of Research on Women’s Health recommended as early as 2010 that pregnant women 
should be considered as a scientifically complex rather than vulnerable group, this being for the 
reason that this group has the same capacity and autonomy for decision making as its nonpreg-
nant counterparts, including the decision of whether or not to participate in a clinical trial [3].
Scientific complexity arises from the special physiological conditions of pregnancy and from 
the ethical considerations of the balance between maternal well-being and fetal well-being.
Pregnancy is accompanied by important physiological changes and their knowledge is an 
element of great value for the proper management of the obstetric patient. Practically, all 
the body’s system of the pregnant woman is adapted to house the product, among them are 
changes at the ocular, musculoskeletal, skin and mucous, hepatic, hematological, renal, and 
gastrointestinal levels. The most relevant changes occur at the uterine level, systemic vascular 
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resistance is reduced due to high flow and low resistance circuit in the uteroplacental circu-
lation. In pregnancy, uterine blood flow significantly increases to allow perfusion of inter-
villous placental spaces and fetal development. The trophoblast invades the uterine spiral 
arteries; vascular smooth muscle cells are lost and replaced by the fibrinoid material, convert-
ing them into large dilated blood vessels allowing greater perfusion of the placenta [4]. These 
changes pose a challenge for the researcher as they make it very difficult to define not only 
the possible therapeutic results of an intervention, but also to adapt the intervention to these 
new changes that are not present in nonpregnant women. In a pathological condition such 
as preeclampsia, this may represent a greater challenge, because of restrictions on research 
in a physiological pregnancy, ignorance or doubts about the effects of the intervention on the 
organism, or pathological adaptations that may affect the intervention that is intended to be 
performed are greater.
The ethical complexity is established in the possibility that the intervention applied in key 
phases causes a teratogenic risk or that affects the adaptation of the product to extrauterine 
life, and more worrying, the possibility of long-term toxicity. This is why it is necessary that 
preclinical teratogenicity studies have been completed prior to the intervention in pregnant 
women. Also, it is recommended to start the new interventions after the 12th week of gesta-
tion, when the organogenesis is finished and finally, it is recommended to follow the fetus and 
newborn [5]. However, these special considerations do not seem to be sufficient, as there are 
currently two forms of research in the group of pregnant women: the first consists of interven-
tions unrelated to pregnancy that may benefit only the mother [3]. It seems that the previous 
recommendations were formulated with this type of research, since the use of thalidomide 
has contemplated the possibility of developing drugs that may attenuate different discomforts 
during pregnancy. The clinical investigation currently has to verify that the pharmacologi-
cal interventions do not cause damage to the product and not only benefit the mother. The 
second type of research concerns interventions that may potentially benefit the mother and 
her fetus [3]. This aspect is more related to the development of pharmacological interventions 
for pathologies in pregnancy, specifically speaking of preeclampsia, the treatments are not 
indicated at the same time for the mother and for the fetus. Betamimetics used to prevent 
preterm birth are not intended to treat the mother and may even complicate maternal health. 
In contrast, depending on the severity of hypertension, the drugs could have a toxic effect on 
the fetus. These two aspects should be considered when deciding to experiment with a new 
therapeutic product or scheme [5].
3. Fetal well-being in the clinical trial
When deciding that the study population is the group of pregnant women, the first ethical cri-
teria that need to be reviewed are those aimed at the protection of the fetus. Generally, inves-
tigations of pregnant women involving an intervention or experimental procedure such as in 
PE cases, should not expose the embryo or fetus to a greater risk than the minimum, except 
when the use of the intervention or procedure is justified for saving the life of the mother. 
However, in addition to a deep and sufficient knowledge of the intervention that is proposed 
to apply, there is no strategy to evaluate during the course of research the side effects on the 
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product. Although maternal-fetal medicine is currently a fact, with several diagnostic imag-
ing and biochemical resources, with established therapeutic procedures, there is no consensus 
on what tests are necessary to perform and monitor the product during investigations in preg-
nant women. Even experts do not dare to indicate any fetal diagnostic procedure, within the 
clinic in the management of pathological pregnancies, but it is at the discretion of the attend-
ing physician the use of some diagnostic or therapeutic techniques [6].
There are six most generalized methods to know and evaluate fetal well-being [7]:
1. Maternal evaluation of fetal activity. It consists of the count by the mother of the number 
of times fetal movement occurs. Although the fetal movement count is a recommendation 
that is made to every pregnant woman, there is no cutoff point when abnormal movement 
is considered abnormal, some clinicians mark the alarm in less than 10 fetal movements 
perceived per day, others when no movements are perceived within 2 h. This form of as-
sessment of fetal well-being presents a false-positive rate, since it depends on the subjectiv-
ity of the mother.
2. Test without stress. It consists of the evaluation of fetal heart rate in relationship to uterine 
contractions. Although it has a low false-negative rate (0.19–1%), its high rate of false posi-
tives (55%) makes it a test with minimal benefits, and its counterpart, the stress test, in which 
it is administered by infusion intravenous oxytocin, is contraindicated in high-risk situations.
3. Biophysical profile. It is a test composed of the evaluation of five parameters, fetal heart 
activity, fetal respiratory movements, fetal thick movements, muscle tone, and volume of 
amniotic fluid. Although its false-negative rates are very low (0.07%), its false-positive rate 
is only lower than that of the stress-free test, and has not shown any difference in terms of 
fetal death, cesarean indication, and under Apgar score. In addition to being a dependent 
operator test, factors that may alter outcomes include hypoxemia, gestational age, steroid 
administration, magnesium sulfate administration, and labor; five factors that occur fre-
quently in pregnant women with PE.
4. Modified biophysical profile. It is the combination of the stress-free test with the biophysi-
cal profile. Although it requires less time and experience for its realization, makes its result 
more reliable, its false-positive and -negative rates are similar to the two tests separately.
5. Fetal Doppler ultrasound. The evaluation consists in measuring by ultrasound the velocity 
of blood flow in the fetal vessels, usually the umbilical artery. Out of all of the above, Dop-
pler has been evaluated with the most rigorous clinical trials and although it does not show 
a benefit in terms of fetal death in high-risk pregnancies, it has become an effective test in the 
reduction of fetal morbidity and mortality in high-risk pregnancies, being this an indication 
for its use. The use of Doppler in pregnant women with high risk of PE can be a predictive 
tool combined with serum biomarkers; this strategy is still being validated but promising.
6. Evaluation of fetal lung maturity. It consists the evaluating the presence of surfactant fac-
tor in the amniotic fluid. It is a useful evaluation when it is necessary to determine the best 
time to interrupt the pregnancy when the risk of continuing it is greater. Due to the fact 
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that in PE the treatment consists of the interruption of pregnancy, to be able to prolong it 
until reaching the fetal maturity, becomes one of the most difficult aspects of the manage-
ment to avoid the fetal morbidity-mortality, reason why it is to make sure that the fetus 
counts with pulmonary maturity to resist extrauterine life has become essential.
Although these tests and diagnostic interventions are the most used in the clinic, the amount 
of imaging tests, serum markers, and procedures with maternal-fetal medicine is higher; how-
ever, many of the tests have not shown their value, they could be useful and applicable reason 
why they require to be studied, especially those that allow predicting the presentation of 
complications or diseases such as PE. Among the currently available tests are the evaluation 
of both fetal DNA and the cells that make up the placenta, even in an experimental way, it is 
possible to attenuate or increase gene expression through miRNAs, not only for diagnostic 
purposes, but also for possible therapeutic applications in the future.
The American Congress of Obstetricians and Gynecologists states that the evaluation of fetal 
well-being may be appropriate for pregnancies with an increased risk of fetal involvement; 
however, there are no comprehensive trials demonstrating the benefit of all tests and their 
potential indications. On the other hand, experts recommend carrying out tests of fetal well-
being in cases of diabetes, uterine growth restriction, and hypertension [7].
As we can see that there are no specific guidelines on how to evaluate fetal well-being during 
pregnancy routinely in the clinic, and this deficiency is translated into clinical research with 
pregnant women. As mentioned before, although one of the principles of research in preg-
nancy is to maintain the integrity of the product, there are neither guidelines nor recommen-
dations on which tests to apply and when to ensure the safety of the fetus. From the above, we 
can infer that most clinical trials involving pregnant women have not been able to guarantee 
or know with certainty the fetal well-being. So how is it possible to monitor fetal well-being in 
a clinical trial? How can we evaluate adverse effects on the product? And if there is no strat-
egy to assess at least fetal well-being, is it ethical to allow the participation of pregnant women 
in clinical trials? It is up to the researcher to decide the degree of safety with which he plans 
to conduct his research, and in the absence of additional tests to ensure fetal well-being, using 
those available is the most reasonable. However, we should not be satisfied with the analysis 
of the structural function to guarantee the innocuousness of an intervention, it is necessary to 
find strategies that in fact allow to evaluate not only the welfare, structural integrity, and fetal 
vitality, but also to value the whole range of possible adverse effects, both acute and chronic, 
that may be occurring as a result of new pharmacological interventions or procedures.
4. Clinical research in women pregnant with PE
Pregnancy is a physiological condition inherent in almost all species and life; however, it 
is one of the lesser known states and a field of research that just begins to grow, because at 
the beginning of research with pregnant women, a series of events occurred that negatively 
marked research in this population.
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Research is now making its way into the subject of pregnancy and its pathologies in order to 
have a better understanding of physiological processes and to reduce maternal-fetal morbid-
ity and mortality. However, despite the intentions and efforts of researchers, little is known. 
In the context of PE, it has been possible to trace its origin to the inadequate invasion of the 
trophoblastic villi on the vascular bed of the uterine spiral arteries, little is known about the 
cause of this inadequate adaptation of the uteroplacental vascular system [8]. Moreover, we 
are in complete disbelief about why some women develop PE and others do not. There is no 
effective diagnostic test to predict who will have PE, the best biomarkers have poor predictive 
power, the best chance to achieve prevention so far arises from the combination of Doppler 
ultrasound with some of the serum markers, which have been implemented, nevertheless, 
only demonstrate efficacy once the first evident changes of PE are presented, when it is no 
longer possible to avoid the development of the disease [9]. A real opportunity for prevention 
of PE would arise from a marker that would allow us to know with great certainty, which 
women are at risk of having PE, even before the pregnancy is carried out. The best predictive 
tool we have are the risk factors that have been determined by both prospective and retro-
spective studies, but are only able to predict 30% of women who develop PE [9], there is even 
a larger group of the population that develops PE with no previous risk factors. On the other 
hand, from the group of women who develop PE, one part shows severe PE and another 
group develops eclampsia, and again it is not possible for the treating doctors to determine 
who and how they evolve to more serious stages.
In women with severe PE, who present it before fetal viability, maternal stabilization is rec-
ommended before interruption of pregnancy. Once treatment is established, close monitoring 
is required to identify the presence of serious complications of PE. Despite efforts to treat PE, 
treatment is symptom-based and focused on controlling blood pressure. In regard to the time 
of delivery, gestational age should transfer to the maximum possible. However, in severe PE, 
in addition to antihypertensive treatment, termination of pregnancy is recommended if it is 
greater than 34 weeks. If the pregnancy is less than 34 weeks and the mother and product are 
stable, the pregnancy should be continued with administration of corticosteroids. Currently, 
there are multiple criteria for better management of PE, but the only cure for PE is termination 
of pregnancy. This results in a difficult decision for the physician and the mother because of 
the psychological burden, and the social and economic morbidity [8].
The results of medical interventions have failed to significantly decrease the morbidity and 
mortality of PE. The main reason for this failure could be the multifactorial origin of patho-
genic processes that lead to the development of PE. Therefore, the approach for management 
of patients with PE is preventing its late occurrence in pregnancy. The key to prevention of 
PE is knowledge of the factors that trigger pathophysiological processes that culminate in 
the presentation of the PE. However, efforts to understand the origin of these processes are 
still poorly or incompletely understood. There is a lack of knowledge because the approach 
to study this population may be unethical compared with diseases of nonpregnant women 
[10]. The multifactorial origin of PE and difficulty of carrying out an investigation in the early 
stages of pregnancy, because it can endanger the mother and fetus, have made research dif-
ficult. Understanding the developmental characteristics of the placenta in pregnancy at high 
risk for PE is essential for understanding the pathophysiology and for developing strategies 
of prevention [8].
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5. Current state of research about PE
There are currently 236,008 clinical trials registered in clinicalTrials.gov, from which only 
3% are focused on pregnancy, and among them 6.4% are about PE. Of all clinical trials dedi-
cated to PE, 47.9% focus on strategies to improve treatment, 22.2% of the clinical trials aim 
to improve the diagnosis or its establishment in the early stages, and 16.7% aim to establish 
the utility of new biomarkers, for both diagnostic and monitoring. Finally, only 10.7% of the 
clinical trials registered until February 1, 2017 are focused on the prevention of PE (Figure 1).
Another aspect that should be taken under consideration is that more than half of the clini-
cal trials directed to PE are carried out in regions classified as first world such as Europe and 
North America, whereas research in the rest of the world only constitutes 40%, despite the fact 
that developing countries are the ones that bear the greatest burden of morbidity and mortal-
ity caused by this disease (Figure 2).
In our times, PE has a worldwide relevance and it has been increasing over the years. Clinical 
trials with the objective of reducing the morbidity and mortality of this pathology have also 
increased over time. The previous chart denotes some of the terminated trials registered in clin-
icaltrials.gov, many of which have certain limitations that we were able to observe (Table 1).
In the study titled, “l-arginine and antioxidant vitamins during pregnancy to reduce pre-
eclampsia”, there is little coherence between the objective and the design of the study. Although 
Figure 1. Clinical trials registered until February 1, 2017. Data from: clinicaltrials.gov.
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it is known that the production of nitric oxide and l-arginine as the main substrate of nitric 
oxide synthase is involved in the pathophysiology of PE, the study design is directed at the 
effect of l-arginine that has on the development of PE; however, levels of l-arginine are not 
evaluated at any moment, neither its nitrates nor nitrites, being the reason why this design can-
not help reach the hypothesis. In addition, the main inclusion criteria appeared to be having a 
high-risk profile for developing PE; however, high-risk factors such as diabetes, autoimmune 
diseases, and hypertension in pregnancy and kidney diseases are not considered as inclu-
sion criteria, and these factors combined with a history of risk of developing PE in previous 
pregnancies, increase up to nine times the risk of developing PE. Another mistake that can be 
found in their design is noted when analyzing the main conclusion and the way the interven-
tion was carried out, the conclusion states that the supplementation of l-arginine and vitamins 
reduces the incidence of PE; nevertheless, in the results it can appreciated that the group that 
only received the food-bar containing the vitamins did not have a significant reduction in the 
risk of developing PE. Meaning that the mayor contributing factor for the reduction of PE was 
indeed l-arginine and not the combination of l-arginine/vitamins, and these would have been 
more notorious if a supplementation group taking only l-arginine was added [11].
In the study titled “Usefulness of Extracorporeal Removal of sFLT-1 in Women with Very Early 
Severe Preeclampsia (ADENA)”, at first instance we are lead to appreciate that the primary 
outcome of the study is about early severe PE; however, later, we appreciate that the intention 
is improving perinatal death as the primary outcome. The first comment worth mentioning is 
that using words such as “improving” in an investigation study may be to imprecise, it is better 
to use terms such as “reducing” for this instance. Moreover the levels of sFLT-1 are not per say 
an inclusion criteria for deciding whether or not to perform apheresis, even by being quantified 
before and after the intervention, those women with high levels of sFLT-1 could perhaps have a 
Figure 2. Clinical trials on PE reported by region.
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Title Hypothesis Population Intervention Conclusions
L-Arginine and 
Antioxidant 
Vitamins during 
Pregnancy to Reduce 
Preeclampsia
To test that a 
relative deficiency of 
L-arginine, precursor 
of nitric oxide (NO) 
by the enzyme NO 
synthase (NOS), reduces 
the development of 
preeclampsia in high-
risk pregnancies
Pregnant women 
with a history of a 
previous pregnancy 
complicated by 
preeclampsia, or 
preeclampsia in a 
first degree relative, 
whom are deemed 
to have an increased 
risk of recurrence 
of the disease, 
were studied from 
14 to 32 weeks 
of gestation and 
followed until 
delivery
Supplementation with: 
medical food-bars 
containing L-arginine 
plus antioxidant 
vitamins, antioxidant 
vitamins alone or 
placebo
Supplementation 
during pregnancy 
with a medical 
food containing 
L-arginine and 
antioxidant 
vitamins reduced 
the incidence of 
preeclampsia 
in high-risk 
pregnancy
Usefulness of 
Extracorporeal 
Removal of sFLT-1 
in women with 
very early severe 
Preeclampsia 
(ADENA)
The removal of s-Flt1 
improves perinatal 
death in women with 
very early severe 
preeclampsia
Women with 
singleton pregnancy 
having severe 
preeclampsia at 
23–25 6/7 weeks of 
gestation
Apheresis for 
extracorporal removal 
of sFlt-1
Does not have a 
result
Oral Progesterone 
and Low Dose 
Aspirin in the 
Prevention of 
Preeclampsia
Low-dose aspirin 
combined with 
progesterone will 
decrease the risk 
of preeclampsia in 
pregnant women with 
history of preeclampsia 
in a previous 
pregnancy
Pregnant patients 
with a previous 
history of 
preeclampsia in the 
immediate prior 
pregnancy
Aspirin 81 mg once a 
day orally, progesterone 
200 mg twice daily
Does not have a 
result
Safety and Efficacy 
of RLX030 in 
Pregnant Women 
with Preeclampsia
Part 1: To assess the 
safety and tolerability 
of different doses of 
RLX030, when given 
to pregnant women 
with preeclampsia. Part 
2: To assess whether 
an optimal dose of 
RLX030 can prolong 
pregnancy in women 
with preeclampsia
Pregnant women in 
28 weeks (0 days) 
and 33 weeks (+4 
days) of gestational 
age with a diagnosis 
of preeclampsia 
or superimposed 
preeclampsia 
requiring 
hospitalization
RLX030 15 μg/kg/day IV 
for 72 h
Not enough 
information 
was provided to 
analyze because 
the study was 
stopped after 
three patients 
were enrolled
CPAP in 
Preeclampsia
To assess the effects 
of nasal CPAP in 
pregnant women (24–
37 gestational weeks) 
with preeclampsia
Women with 24–37 
weeks of pregnancy 
with Singleton 
pregnancy, 
primiparous 
and primigravid 
diagnosis of 
preeclampsia
Continuous Positive 
Airway Pressure 
Ventilation (CPAP)
Does not have 
result
Source: Clinicaltrials.gov [11].
Table 1. Current state of clinical trials about PE.
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greater benefit, reason why stabilizing grades at first instance could help the obstetrician make 
a better clinical decision. Finally, although its justifiable not using a control group, this type of 
design (before and after), not having a reference group, leads to a lower internal validity [11].
In the study titled “Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia”, 
the main inclusion criterion is having a history with preeclampsia. Nevertheless, other factors 
of high risk were not taken account. Even though the study propounds that a deficiency of 
progesterone could lead to PE and in consequence, supplementation with progesterone could 
reduce the incidence of PE, serum values as an indicator to identify patients whom could 
benefit with progesterone supplementation were not taken into account. The comparison 
between before and after instead of vs the placebo group is also an inconvenient [11].
In the study titled “Oral Progesterone and Low-Dose Aspirin in Preeclampsia Prevention,” 
the main inclusion criterion is the antecedent of PE in previous pregnancies; however, as in 
the previous study, other factors that increase the risk are not taken into account. The study 
assumes that a deficiency of progesterone could be the cause of PE, this argument seems to 
be the rationale to reduce the incidence of PE using supplementation with progesterone; but 
in the study, they did not take serum values in consideration as a marker to indicate which 
patients could benefit from supplementation. This study, as the previous one, also lacks the 
comparison against a placebo group, creating the same limitations [11].
In the study entitled “Safety and Efficacy of RLX030 in Pregnant Women with Pre-Eclampsia” 
proposed by the company NOVARTIS did not have sufficient information to perform an anal-
ysis, because of premature termination of the study [11].
In the study entitled “CPAP in Preeclampsia”, the main objective is the evaluation of fetal well-
being using nasal continuous positive airway pressure (CPAP) as a basis to increase fetal oxy-
genation; however, monitoring fetal movements is a scarce strategy to evaluate fetal well-being 
and it could be enhanced, according to the advances in fetal medicine to allow us to get closer 
to knowing the well-being of the fetus. The study did not make a distinction on the severity of 
PE, and if a clinical benefit of using CPAP is demonstrated, a distinction on the severity might 
be useful for clinical decisions. Therefore, the rationale to use CPAP is not clear [11].
In several studies, narrowing gestational age as inclusion criteria perhaps increases internal 
validity; however, the results cannot be extrapolated to other groups [11].
It is worth noting that the protocols registered in clinical trial go through variations during 
the study, which go unnoticed.
6. Transference of scientific knowledge to clinical practice persist  
in LAG
One of the most important advantages of basic research is the possibility to transfer 
knowledge to improve clinical practice. However, in the case of PE, new information 
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regarding new biomarkers and new opportunities of intervention emerge every year, but 
these are not implemented by the treating physicians. Moreover, clinical practice guide-
lines are lagging too, and many years pass before a new intervention reaches the level 
of recommendation within them. On the one hand, this occurs because the information 
that is generated seems to be isolated and fragmented, there is no body or work team or 
expert committee that focus their efforts on trying to solve the problem or on generating 
a line of research on the subject. Another part of the transforming knowledge problem 
is that for this to be carried out it is necessary that the information obtained may be 
applicable to different populations at different times and with different characteristics, 
this is very complex to achieve in the first place because, as mentioned previously, there 
is no focus group to this and separated efforts generate a bias in the study population. 
Another bias that impedes transfer is that the risk factors presented by each population 
are different in the developed countries than those in the developing world, so informa-
tion generated on the one side is not necessarily applicable in other parts of the world. 
Because the origin of PE is not well understood, the approaches with which the different 
studies are developed differ, while some may determine that the cause is oxidative stress, 
some others may argue that the cause is genetic. The truth is that so far it is considered 
multifactorial and because of this the international guidelines are more discreet about 
which recommendations to accept, in the sense of being able to verify which actions will 
have an evident weight in clinical practice.
Finally, one of the most worrying aspects that delay the transfer of knowledge is the lack 
of medical update on the subject. A very obvious example is that in practice, physicians do 
not intentionally seek pregnancies with a high risk of PE, and when a patient is classified 
with high risk, the first action of the doctor is an expectant management, without any inter-
vention, although in the guidelines of clinical practice the administration of acetylsalicylic 
acid, calcium, and l-arginine is recommended, this happens because evidence of acetylsali-
cylic acid’s efficacy in reducing the risk is contradictory, while calcium intake is reserved for 
those women with low risk and low calcium intake, and l-arginine, although it is part of the 
Canadian guide, no dosage or time is specified.
Other evidence in the lack of management of the subject in some specialists is the lack of com-
munication they generate with patients who are at high risk. Patients are not informed of their 
situation and expectant management “poor surveillance” continues even after the patient 
develops PE, which is when the symptomatic management begins, and it seems that the phy-
sicians are waiting for a complication to occur, to make the decision of taking a more active 
management. It is true that during the 1st weeks of the PE, there are not many recommenda-
tions, and that most focus on the final stages in which fetal viability can be achieved, but this 
same reason should be what drives medical doctors to have a closer monitoring in research 
opportunities and new information to improve the outcome of the pregnancy, remembering 
that once PE is presented, there is no curative treatment, beyond the interruption of preg-
nancy. Efforts should be directed at preventing the occurrence of PE or, failing at that, occur-
ring late in pregnancy.
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